Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Equity Average (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Equity Average for 9 consecutive years, with $47.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 52.0% to $47.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.1 million, a 52.0% decrease, with the full-year FY2024 number at $76.3 million, up 30.59% from a year prior.
  • Equity Average was $47.1 million for Q3 2025 at Rein Therapeutics, down from $48.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $98.1 million in Q3 2024 to a low of $12.0 million in Q3 2023.
  • A 5-year average of $48.6 million and a median of $47.1 million in 2025 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: crashed 58.89% in 2023, then soared 717.99% in 2024.
  • Rein Therapeutics' Equity Average stood at $47.0 million in 2021, then crashed by 56.05% to $20.7 million in 2022, then soared by 165.0% to $54.7 million in 2023, then surged by 36.65% to $74.8 million in 2024, then plummeted by 37.04% to $47.1 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Equity Average are $47.1 million (Q3 2025), $48.9 million (Q2 2025), and $52.1 million (Q1 2025).